The biologic importance of tumor-infiltrating lymphocytes

Journal of Cutaneous Pathology

Volumn 37, Issue SUPPL. 1, 2010, Pages 48-53

  Hodi, F Stephen ^a,b,c   Dranoff, Glenn ^a,b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b Department of Medicine ^*  (Canada)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LEUKOCYTE ANTIGEN;

ARTICLE; BIOPSY; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; MELANOMA; PATHOLOGY; PROGNOSIS; SKIN TUMOR;

ANTIGENS, CD; BIOPSY; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY; MELANOMA; PROGNOSIS; SKIN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 77949826710     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/j.1600-0560.2010.01506.x     Document Type: Article

References (69)

1. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004 4 : 11.
2. Dougan M, Dranoff G. Immune therapy for cancer. Annu Rev Immunol 2009 27 : 83.
3. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986 315 : 1650.
4. Dougan M, Dranoff G. Inciting inflammation: the RAGE about tumor promotion. J Exp Med 2008 205 : 267.
5. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005 5 : 749.
6. Clark W, From L, Bernardino E, Mihm M. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 1969 29 : 705.
7. Ferradini L, Mackensen A, Genevee C, et al. Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. J Clin Invest 1993 91 : 1183.
8. Mackensen A, Carcelain G, Viel S, et al. Direct evidence to support the immunosurveillance concept in a human regressive melanoma. J Clin Invest 1994 93 : 1397.
9. van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991 254 : 1643.
10. Bulkley G, Cohen M, Banks P, Char D, Ketcham A. Long-term spontaneous regression of malignant melanoma with visceral metastases: report of a case with immunologic profile. Cancer 1975 36 : 485.
11. Clark W, Elder D, Guerry D, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989 81 : 1893.
12. Clemente C, Mihm M, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996 77 : 1303.
13. Mihm M, Clemente C, Cascinelli N. Tumor infiltrating lymphocytes in lymph node melanoma metastases-a histopathologic prognostic indicator and an expression of local immune response. Lab Invest 1996 74 : 43.
14. Zhang L, Conejo-Garcia J, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Eng J Med 2003 348 : 203.
15. Naito Y, Saito K, Shiiba K, et al. CD 8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998 58 : 3491.
16. Pages F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005 353 : 2654.
17. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006 313 : 1960.
18. Nakano O, Sato M, Naito Y, et al. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res 2001 61 : 5132.
19. Dieu-Nosjean MC, Antoine M, Danel C, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008 26 : 4410.
20. Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004 351 : 2159.
21. Brunkow ME, Jeffery EW, Hjerrild KA, et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001 27 : 68.
22. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD 4 + CD 25+ regulatory T cells. Nat Immunol 2003 4 : 330.
23. Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 2005 22 : 329.
24. Ochs HD, Ziegler SF, Torgerson TR. FOXP3 acts as a rheostat of the immune response. Immunol Rev 2005 203 : 156.
25. Sakaguchi S. Naturally arising Foxp3-expressing CD25+ CD 4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005 6 : 345.
26. Apostolou I, von Boehmer H. In vivo instruction of suppressor commitment in naive T cells. J Exp Med 2004 199 : 1401.
27. + suppressor T cells: more questions than answers. Nat Rev Immunol 2002 2 : 389.
28. Chen ML, Pittet MJ, Gorelik L, et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci USA 2005 102 : 419.
29. Nishikawa H, Kato T, Tanida K, et al. CD 4+ CD 25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses. Proc Natl Acad Sci USA 2003 100 : 10902.
30. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD 25+ CD 4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999 163 : 5211.
31. Yu P, Lee Y, Liu W, et al. Intratumor depletion of CD 4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med 2005 201 : 779.
32. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004 10 : 942.
33. Sato E, Olson SH, Ahn J, et al. Intraepithelial CD 8+ tumor-infiltrating lymphocytes and a high CD 8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005 102 : 18538.
34. Gao Q, Qiu SJ, Fan J, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007 25 : 2586.
35. Bates GJ, Fox SB, Han C, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006 24 : 5373.
36. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005 23 : 515.
37. Hamanishi J, Mandai M, Iwasaki M, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD 8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 2007 104 : 3360.
38. Nomi T, Sho M, Akahori T, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 2007 13 : 2151.
39. Thompson RH, Dong H, Lohse CM, et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res 2007 13 : 1757.
40. Gao Q, Wang XY, Qiu SJ, et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 2009 15 : 971.
41. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993 90 : 3539.
42. Mach N, Gillessen S, Wilson SB, Sheehan C, Mihm M, Dranoff G. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or flt3-ligand. Cancer Res 2000 60 : 3239.
43. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994 264 : 961.
44. + T cells in the antitumor immune response. J Exp Med 1998 188 : 2357.
45. Reilly R, Machiels J-P, Emens L, et al. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. Cancer Res 2001 61 : 880.
46. Gillessen S, Naumov YN, Nieuwenhuis EE, et al. CD1d-restricted T cells regulate dendritic cell function and antitumor immunity in a granulocyte-macrophage colony-stimulating factor-dependent fashion. Proc Natl Acad Sci USA 2003 100 : 8874.
47. Soiffer R, Lynch T, Mihm M, et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor generates potent anti-tumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA 1998 95 : 13141.
48. Soiffer R, Hodi FS, Haluska F, et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 2003 21 : 3343.
49. Hodi FS, Dranoff G. Combinatorial cancer immunotherapy. Adv Immunol 2006 90 : 337.
50. Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 2001 19 : 565.
51. Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenuator. Immunity 1997 7 : 445.
52. Doyle AM, Mullen AC, Villarino AV, et al. Induction of cytotoxic T lymphocyte antigen 4 (CTLA-4) restricts clonal expansion of helper T cells. J Exp Med 2001 194 : 893.
53. Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 2001 19 : 225.
54. Hori S, Takahashi T, Sakaguchi S. Control of autoimmunity by naturally arising regulatory CD 4+ T cells. Adv Immunol 2003 81 : 331.
55. Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp 3+ regulatory T cell function. Science 2008 322 : 271.
56. Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995 270 : 985.
57. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995 3 : 541.
58. Chambers CA, Sullivan TJ, Allison JP. Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD 4+ T cells. Immunity 1997 7 : 885.
59. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996 271 : 1734.
60. Yang YF, Zou JP, Mu J, et al. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages. Cancer Res 1997 57 : 4036.
61. Kwon ED, Hurwitz AA, Foster BA, et al. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci USA 1997 94 : 8099.
62. Mokyr MB, Kalinichenko T, Gorelik L, Bluestone JA. Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice. Cancer Res 1998 58 : 5301.
63. van Elsas A, Hurwitz A, Allison J. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999 190 : 355.
64. van Elsas A, Sutmuller RP, Hurwitz AA, et al. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J Exp Med 2001 194 : 481.
65. Hurwitz A, Yu T, Leach D, Allison J. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci USA 1998 95 : 10067.
66. Hurwitz AA, Foster BA, Kwon ED, et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 2000 60 : 2444.
67. Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 2006 116 : 1935.
68. Hodi FS, Mihm MC, Soiffer RJ, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 2003 100 : 4712.
69. Hodi FS, Butler M, Oble DA, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 2008 105 : 3005.